Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 514
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 151–151 of 151 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04539977	PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer	recruiting	Phase 2	40	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	May 9, 2023	clinicaltrials